Browse studies

Find your next paid study

149 recruiting studies matching your filters

A Phase II, Randomized, Double-Blind, Placebo- Controlled Study of Ensifentrine in Subjects With Non-Cystic Fibrosis Bronchiectasis

This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) deli…

Non-cystic Fibrosis Bronchiectasis

Estimated

~$75 – $2,800

Actual pay is set by the research site.

Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USANCT06559150

Observational

Novel Point-of-care Sweat Chloride Testing Device for Monitoring CFTR Function

This study is being done to test a device called micro Sweat Test Patch (mSTP or µSTP). The study team will compare the standard of care (SOC) method of sweat…

Cystic Fibrosis

Estimated

~$10 – $750

Actual pay is set by the research site.

Emory UniversityNCT07414810

Role of Genetic Factors in the Pathogenesis of Lung Disease

This study is designed to evaluate the genetics involved in the development of lung disease by surveying genes involved in the process of breathing and examini…

Cystic FibrosisPulmonary FibrosisTuberous Sclerosis+2 more

Estimated

~$10 – $675

Actual pay is set by the research site.

National Heart, Lung, and Blood Institute (NHLBI)NCT00001532

International Pleuropulmonary Blastoma/DICER1 Registry (for PPB, DICER1 and Associated Conditions)

PPB has strong genetic implications, with a unique set of conditions in an individual or their family, occurring mostly in childhood and adolescence. The Inter…

Pleuropulmonary BlastomaSertoli-Leydig Cell TumorDICER1 Syndrome+17 more

Estimated

~$10 – $750

Actual pay is set by the research site.

Children's Hospitals and Clinics of MinnesotaNCT03382158

Phase 3

A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 18 Years of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

To evaluate the pharmacodynamics and safety of tolvaptan in pediatric subjects with ARPKD

Autosomal Recessive Polycystic Kidney (ARPKD)

Estimated

~$50 – $2,100

Actual pay is set by the research site.

Otsuka Pharmaceutical Development & Commercialization, Inc.NCT04782258